Redmile Group has raised $30 million for its Redmile Biopharma Investments I, according to a SEC filing. The San Francisco-headquartered firm began fundraising in 2015 with a $150 million target.
The fund will target venture capital opportunities in healthcare sectors in North America.Â
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: